Aktie 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Aktien

2315

CNE100005D27

2315

Schlusskurs Hong Kong S.E.
Andere Börsenplätze
 00:00:00 24.05.2024 		% 5 Tage % 1. Jan.
9,56 CNY -2,05 % Intraday Chart für Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +0,10 % -20,20 %
06.05. Biocytogen schließt mit Biocopy eine Vereinbarung zur Evaluierung und potenziellen Lizenzierung von TCR-mimischen Antikörpern ab CI
26.04. Verlust von Biocytogen Pharmaceuticals verringert sich 2023 MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies
Biocytogen Pharmaceuticals' Loss Narrows in 2023
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 2315 Aktie
  4. Nachrichten Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  5. Andere Sprachen